Primary Central Nervous System Lymphoma Expressing the Human Neurotropic Polyomavirus, JC Virus, Genome

Valle, Luis Del; Enam, Sahnila; Lara, César Barboza; Miklóssy, Judith; Khalili, Kamel; Gordon, Jennifer

doi:10.1128/jvi.78.7.3462-3469.2004

Cited by 46 publications

(44 citation statements)

References 37 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another laboratory reported JCV and BKV sequences in 5% and 6% of 83 lymphomas, respectively (18). Finally, a report of JCV DNA sequences identified 81% of 27 central nervous system lymphomas analyzed (19). Some investigators have proposed that JCV may contribute to the development of cancer through a ''hit-and-run'' mechanism, whereby the virus is involved in the early stages of carcinogenesis and is eventually lost from malignant cells through subsequent mutations (31).…”

Section: Discussionmentioning

confidence: 99%

“…Because both latent EBV and polyomavirus infections can reactivate under conditions of immunosuppression to cause disease, and JCV and EBV sequences have been shown to be present in NHL tissues simultaneously (19), we also assessed whether there was an additive effect of EBV and JCV or BKV infection on the risk of NHL in the subset of participants for whom both EBV and polyomavirus antibody data were available. This subset differs slightly from the previous study due to missing EBV data and replacement of controls from the 1994 study who were subsequently diagnosed with cancer or whose banked serum was depleted.…”

Section: Methodsmentioning

confidence: 99%

“…JCV has been shown to infect B-lymphocytes (14,15), and Neel and colleagues have described chromosomal damage in lymphocytes associated with both JCV (16,17) and BKV (16) infections. Some investigators have detected polyomavirus sequences from NHL tissues, including one laboratory that detected JCV and BKV sequences in 5% and 6% of 83 lymphomas, respectively (18) and a recent report that showed the presence of JCV DNA sequences in 22 of 27 B-cell lymphomas of the central nervous system, a subset of which also contained EBV DNA (19).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prediagnostic Circulating Antibodies to JC and BK Human Polyomaviruses and Risk of Non-Hodgkin Lymphoma

Rollison¹,

Engels²,

Halsey³

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Viral infections have been associated with increased risk of non -Hodgkin's lymphoma (NHL). We conducted a nested case-control study to investigate the association between prediagnostic serum antibodies to the human polyomaviruses, JC (JCV) and BK (BKV), and subsequent risk of NHL. Two research serum banks were established in Washington County, Maryland, in 1974 and1989, with the collection of blood samples from >45,000 volunteers. Incident NHL cases diagnosed through 2002 (n = 170) were identified among participants by linkage to population-based cancer registries. Two controls were matched to each case (n = 340) on age, sex, and blood draw date. Prediagnostic IgG antibodies to JCV and BKV were measured using virus-like particle ELISA. Associations between JCV and BKV antibody seropositivity and NHL were estimated using conditional logistic regression. Overall, neither antibodies to JCV [odds ratio (OR), 0.83; 95% confidence interval (95% CI), 0.56-1.23] nor BKV (OR, 0.98; 95% CI, 0.64-1.48) were associated with an increased risk of NHL. Results were similar after stratification by NHL subtype or induction period and adjustment for EBV seropositivity. Among those who donated blood in both 1974 and 1989, an increase in JCV antibody levels over time was associated with a 4-fold increased risk of NHL compared with a steep decline in antibody levels (OR, 4.59; 95% CI,; P trend = 0.02). Whereas JCV seropositivity was not associated with NHL overall, the finding of an increased risk of NHL associated with increasing antibody levels among those who were seropositive at baseline warrants further research into factors influencing reactivation of JCV infection. (Cancer Epidemiol Biomarkers Prev 2006;15(3):543 -50)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prediagnostic Circulating Antibodies to JC and BK Human Polyomaviruses and Risk of Non-Hodgkin Lymphoma

Rollison¹,

Engels²,

Halsey³

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…A number of human malignancies have been associated with JCPyV including oligodendroglioma, astrocytoma medulloblastoma, ependymoma, and glioblastoma (189,(248)(249)(250)(251) and non-Hodgkin lymphoma (252,253), as well as colorectal carcinoma, and gastric and anal cancer (254)(255)(256)(257)(258)(259)(260).…”

Section: Jcpyv Diseasementioning

confidence: 99%

The human JC polyomavirus (JCPyV): virological background and clinical implications

Hirsch

Kardas

Kranz

et al. 2013

APMIS

138

169

View full text Add to dashboard Cite

JC polyomavirus (JCPyV) was the first of now 12 PyVs detected in humans, when in 1964, PyV particles were revealed by electron microscopy in progressive multifocal leukoencephalopathy (PML) tissues. JCPyV infection is common in 35–70% of the general population, and the virus thereafter persists in the renourinary tract. One third of healthy adults asymptomatically shed JCPyV at approximately 50 000 copies/mL urine. PML is rare having an incidence of <0.3 per 100 000 person years in the general population. This increased to 2.4 per 1000 person years in HIV‐AIDS patients without combination antiretroviral therapy (cART). Recently, PML emerged in multiple sclerosis patients treated with natalizumab to 2.13 cases per 1000 patients. Natalizumab blocks α4‐integrin‐dependent lymphocyte homing to the brain suggesting that not the overall cellular immunodeficiency but local failure of brain immune surveillance is a pivotal factor for PML. Recovering JCPyV‐specific immune control, e.g., by starting cART or discontinuing natalizumab, significantly improves PML survival, but is challenged by the immune reconstitution inflammatory syndrome. Important steps of PML pathogenesis are undefined, and antiviral therapies are lacking. New clues might come from molecular and functional profiling of JCPyV and PML pathology and comparison with other replicative pathologies such as granule cell neuronopathy and (meningo‐)encephalitis, and non‐replicative JCPyV pathology possibly contributing to some malignancies. Given the increasing number of immunologically vulnerable patients, a critical reappraisal of JCPyV infection, replication and disease seems warranted.

show abstract

“…The nuclear presence of the T Ag protein was associated with cell oncosuppressor p53 (Table 1). 62,71 tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Two case studies showed a potential association between JCV and this type of tumor.…”

mentioning

confidence: 99%

A Potential Linkage Between the JC and BK Polyomaviruses and Brain and Urinary Tract Tumors: A Review of the Literature

Carluccio¹,

Signorini²,

Elia³

et al. 2014

Advances in Tumor Virology

View full text Add to dashboard Cite

JC virus (JCV) and BK virus (BKV) belong to the Polyomaviridae family and were the first human polyomaviruses (PyVs) discovered. Both JCV and BKV remain latent in the kidneys and can reactivate in immunocompromised hosts, causing progressive multifocal leukoencephalopathy (PML) and nephropathy, respectively. PyVs induce cell transformation in vitro and in animal models, where they infect non-permissive cells. The molecular mechanisms of tumor formation are based on the large tumor antigen (T Ag) protein, which is able to bind and inactivate pRb and p53, inducing uncontrolled cell cycle progression. Many studies on clinical samples also indicate a positive association between JCV and BKV and human solid tumors; however no direct involvement of PyVs in the development of human cancers has been demonstrated. In this review we focused on the potential association between JCV and BKV with brain and urinary tract tumors, respectively.

show abstract

Primary Central Nervous System Lymphoma Expressing the Human Neurotropic Polyomavirus, JC Virus, Genome

Cited by 46 publications

References 37 publications

Prediagnostic Circulating Antibodies to JC and BK Human Polyomaviruses and Risk of Non-Hodgkin Lymphoma

Prediagnostic Circulating Antibodies to JC and BK Human Polyomaviruses and Risk of Non-Hodgkin Lymphoma

The human JC polyomavirus (JCPyV): virological background and clinical implications

A Potential Linkage Between the JC and BK Polyomaviruses and Brain and Urinary Tract Tumors: A Review of the Literature

Contact Info

Product

Resources

About